NASDAQ:COLL

Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

$34.74
-0.10 (-0.29%)
(As of 04/22/2024 ET)
Today's Range
$34.55
$35.30
50-Day Range
$31.76
$40.91
52-Week Range
$20.83
$40.95
Volume
414,728 shs
Average Volume
430,072 shs
Market Capitalization
$1.14 billion
P/E Ratio
29.44
Dividend Yield
N/A
Price Target
$39.00

Collegium Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
12.3% Upside
$39.00 Price Target
Short Interest
Bearish
23.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
9.59%
From $5.63 to $6.17 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

Medical Sector

552nd out of 910 stocks

Pharmaceutical Preparations Industry

251st out of 426 stocks

COLL stock logo

About Collegium Pharmaceutical Stock (NASDAQ:COLL)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

COLL Stock Price History

COLL Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
Collegium Pharmaceutical Inc.
COLL Mar 2024 50.000 call
5 Best Small Cap Pharma Stocks to Invest In
Collegium Pharmaceutical Q4: The Beat Goes On
Where Collegium Pharmaceutical Stands With Analysts
Q4 2023 Collegium Pharmaceutical Inc Earnings Call
Recap: Collegium Pharmaceutical Q4 Earnings
See More Headlines
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/22/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
197
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.00
High Stock Price Target
$40.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+12.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$48.15 million
Pretax Margin
13.36%

Debt

Sales & Book Value

Annual Sales
$566.77 million
Cash Flow
$10.72 per share
Book Value
$5.99 per share

Miscellaneous

Free Float
31,404,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
1.03
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

COLL Stock Analysis - Frequently Asked Questions

Should I buy or sell Collegium Pharmaceutical stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" COLL shares.
View COLL analyst ratings
or view top-rated stocks.

What is Collegium Pharmaceutical's stock price target for 2024?

5 Wall Street analysts have issued 12-month price targets for Collegium Pharmaceutical's shares. Their COLL share price targets range from $37.00 to $40.00. On average, they predict the company's share price to reach $39.00 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts price targets for COLL
or view top-rated stocks among Wall Street analysts.

How have COLL shares performed in 2024?

Collegium Pharmaceutical's stock was trading at $30.78 at the beginning of the year. Since then, COLL stock has increased by 12.9% and is now trading at $34.74.
View the best growth stocks for 2024 here
.

When is Collegium Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our COLL earnings forecast
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings results on Thursday, February, 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.25. The specialty pharmaceutical company had revenue of $149.75 million for the quarter, compared to analysts' expectations of $147.66 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 107.39% and a net margin of 8.50%.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $583.5 million.

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.21%) and Allspring Global Investments Holdings LLC (0.14%). Insiders that own company stock include Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends
.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COLL) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners